Clinical Trial Update: Study of TPI 287 in Patients With Advanced Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study of TPI-287 in patients with advanced malignancies has completed, evaluating safety and preliminary activity in Non-Hodgkin lymphoma and Hodgkin ly…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• TPI-287

Snippet

Sponsor: Cortice Biosciences, Inc. | Conditions: Neoplasms, Non-Hodgkin Lymphoma | Phase 1 | Status: COMPLETED